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BACKGROUND: The RAS/RAF/MEK/ERK pathway is involved in the balance between melanocyte proliferation and differentiation.
The same pathway is constitutively activated in cutaneous and uveal melanoma (UM) and related to tumour growth and survival.
Whereas mutant BRAF and NRAS are responsible for the activation of the RAS/RAF/MEK/ERK pathway in most cutaneous
melanoma, mutations in these genes are usually absent in UM.
METHODS: We set out to explore the RAS/RAF/MEK/ERK pathway and used mitogen-activated protein kinase profiling and tyrosine
kinase arrays.
RESULTS: We identified Src as a kinase that is associated with ERK1/2 activation in UM. However, low Src levels and reduced ERK1/2
activation in metastatic cell lines suggest that proliferation in metastases can become independent of Src and RAS/RAF/MEK/ERK
signalling. Inhibition of Src led to the growth reduction of primary UM cultures and cell lines, whereas metastatic cell line growth was
only slightly reduced.
CONCLUSION: We identified Src as an important kinase and a potential target for treatment in primary UM. Metastasis cell lines seemed
largely resistant to Src inhibition and indicate that in metastases treatment, a different approach may be required.
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Uveal melanoma (UM) is a rare neoplasm that arises from
melanocytes in the eyes. It usually affects people in their sixties
with an incidence rate of B6–8 new cases per million per year
among Caucasians (Egan et al, 1988; Singh and Topham, 2003).
Little is known about the molecular pathogenesis of UM compared
with cutaneous melanoma (CM). Cutaneous melanoma and UM
share the same embryonic origin and similar histological features,
but mutations that regulate proliferation and cause a loss of
cell-cycle control in CM can hardly be found in UM. Whereas
p16-regulated cell cycle control is targeted by the deletion of
chromosome 9p or by the mutation of CDKN2A in CM, most of
the UM cell lines posses a wild-type p16-encoding gene that is,
however, not expressed because of the epigenetic modification of
the CDKN2A gene (van der Velden et al, 2001). The same may be
true for the activation of the RAS-RAF-MEK-ERK or the classical
mitogen-activated protein kinase (MAPK) pathway. The MAPK
activation is crucial for the development of melanocytic neoplasia,
and a constitutive activation of this pathway has been associated
with many different types of cancer (Goding, 2000; Reddy et al,
2003). In CM, the activation of the MAPK pathway has been shown
to occur by a variety of mechanisms, including autocrine growth
factor stimulation and mutation of the NRAS (20% of cases) and
BRAF (60% of cases) genes (van Elsas et al, 1995; Davies et al,
2002; Satyamoorthy et al, 2003). The BRAF mutations have only
rarely been reported in UM and activating mutations in NRAS,
which are found in 25% of all cancers, have never been reported
(Mooy et al, 1991; Soparker et al, 1993; Cohen et al, 2003; Cruz III
et al, 2003; Edmunds et al, 2003; Rimoldi et al, 2003). However, we
and others have found that UM is heterogeneous and that, with
more sensitive techniques, the percentage of mutant BRAF-positive
UM may be higher (Janssen et al, 2008; Maat et al, 2008). The
lack of mutations in the majority of cells is in contrast with
immunohistochemistry and western blot analysis, which have
shown activation of ERK1/2 in most UM (Rimoldi et al, 2003;
Weber et al, 2003; Zuidervaart et al, 2005). Nevertheless, the phar-
macological inhibition of MAPK/ERK kinases 1 and 2 (MEK1/2)
and the genetic targeting of BRAF with siRNA resulted in a
reduced proliferation of UM cell lines (Lefevre et al, 2004; Calipel
et al, 2006). This indicates that although mutations are absent,
the RAS/RAF/MEK/ERK pathway is essential for UM growth and
suggests that an upstream factor is involved in autonomous UM
proliferation. Recently, c-Kit was shown to be upregulated in UM
and involved in an autocrine loop that also involved the RAS/RAF/
MEK/ERK pathway (Lefevre et al, 2004). An incomplete response
to c-Kit inhibition indicates that additional factors are involved
(Hofmann et al, 2009). In addition, the GNAQ gene was shown to
be mutated in almost half of UM (Van Raamsdonk et al, 2008).
GNAQ is part of the G-protein heterotrimer and represents
the GTP-binding part that couples GPCR signalling to MAPK
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sactivation, which marks it as a potential therapeutic target.
However, targeting downstream signalling molecules may be just
as effective as they may be shared with other mutant pathways.
Tyrosine kinase activity profiling in UM was used to explore the
involved kinases. On the basis of a UM cell line and two related
metastasis cell lines, which revealed reduced ERK1/2 activation
in metastases, we were able to identify Src as a crucial upstream
tyrosine kinase for ERK1/2 activation in primary UM. Unfortu-
nately, metastasis cell lines seemed less dependent on Src and
may indicate that metastasis may require an alternative approach
for intervention.
MATERIALS AND METHODS
Cell lines and tumour material
A total of 11 cell lines derived from primary UM (92.1; OCM-1,
-3 and -8; Mel-202, -270, -285, -290) and UM metastases (OMM-1,
-2.3 and -2.5) were analysed for kinase activity (Kan-Mitchell et al,
1989; Waard-Siebinga et al, 1995; Luyten et al, 1996; Chen et al,
1997). UM cell lines were cultured in RPMI 1640 medium (Gibco,
Paisley, Scotland) supplemented with 3mML -glutamine (Gibco),
2% penicillin/streptomycin and 10% FBS (Hyclone, Logan, UT,
USA). Primary UM was cultured in Amniochrome Pro Medium
(Lonza Group Ltd, Basel, Switzerland). All cell cultures were incu-
bated at 371C in a humidified 5% CO2 atmosphere.
Cell lysates were obtained by lysing cells in M-PER Mammalian
Protein Extract Reagent (Pierce, Rockford, IL, USA), supplemented
with 1% Halt Protease Inhibitor Cocktail, EDTA-free (Pierce) and
1% Halt Phosphatase Inhibitor Cocktail (Pierce). Protein con-
centrations were measured by using the BCA Protein Assay kit
(Pierce). Cell lysates were also acquired from three fresh primary
UM samples obtained by enucleation and from three liver
metastases of three different patients, in whom the diagnosis was
confirmed.
Phospho-MAPK array
The Human Phospho-MAPK Array (R&D Systems, Abingdon, UK)
was used to simultaneously detect the relative levels of nine MAP
kinases and nine other serine/threonine kinases in cell lines, in
primary UM and in liver metastasis. In this array, capture and
control antibodies were spotted in duplicate on nitrocellulose
membranes. Experiments were carried out according to the
manufacturer’s guidelines. In short, cell lysates were diluted and
incubated with the array. After binding of both phosphorylated
and unphosphorylated kinases, unbound material was washed
away. A cocktail of phospho-site-specific biotinylated antibodies
was used to detect phosphorylated proteins through streptavidin-
horseradish peroxidase and chemiluminescence. X-ray films of
the blots were scanned and analysed using G-boxHR (Syngene,
Frederick, MD, USA). Control spots with mouse, goat and rabbit
antibodies were used for background correction.
PamGene tyrosine kinase array
Experiments were carried out using a 4-array semi-automated
system (PamStation 4, PamGene, ’s-Hertogenbosch, The Netherlands)
designed for processing PamChip-4 arrays. The PamChip Tyrosine
Kinase Array (PamGene) contains 144 phospho-peptides, immobi-
lised on a porous microarray surface through the peptide N terminus,
representing tyrosine kinase substrates. Each array was blocked
with 0.2% bovine serum albumin (BSA), fraction V (Calbiochem
Immunochemicals, Merck KGaA, Darmstadt, Germany) by pumping
it through the porous microarray for 30 cycles of 30s. Thereafter,
each array was washed thrice for 8s with 1  ABL Protein Tyrosine
Kinase Reaction Buffer solution (New England Biolabs, Ipswich, MA,
USA). Next, incubation was carried out at 301C with the reaction mix,
containing 5mg cell lysate, 4ml1 0 0   BSA (New England Biolabs),
0.4ml1 0m M ATP (Sigma-Aldrich, Zwijndrecht, The Netherlands) and
0.5ml 1mgml
 1 monoclonal anti-phosphotyrosine FITC conjugate
(clone Py20, Exalpha Biologicals, Maynard, MA, USA), adjusted to
40ml with distilled H2O .T h es a m p l ew a sp u l s e db a c ka n df o r t h
through the porous material for 45 cycles, which is coupled to the
base of a well to maximise reaction kinetics and to reduce analysis
time. At every fifth pump cycle, a 16-bit TIFF image was taken with a
built-in CCD camera (PamGene).
Blocking experiments were carried out with Src family-selective
tyrosine kinase inhibitors, PP1, PP2 (Biomol International, LP, of
Plymouth Meeting, PA, USA) and PP3 (the inactive analogue,
Calbiochem), at an end concentration of 10mM in line with a large
body of literature. Each particular inhibitor was mixed with lysates
of cell lines and tissue, together with the reaction mix just before
incubation on the array.
Acquired data from the PamStation 4 were captured with
the supplied software package BioNavigator (Version 0.3.1;
PamGene). For the purpose of finding differentially phosphory-
lated substrates, data were imported in the LIMMA package
(Bioconductor.org) and we applied the empirical Bayes method
(Smyth, 2004). Background subtracted data were normalised for
differences between experiments, and substrates and P-values of
0.05 or less were corrected for multiple testing using the Benjamini
and Hochberg correction. Substrates with a corrected P-value of
0.05 or less were assumed to be significant.
Western blot analysis
Cell lysates (10mg) were separated on 12.5% SDS–PAGE gels,
and proteins were transferred to Hybond-polyvinyldifluoride
membranes (Amersham Biosciences, Buckinghamshire, UK). The
membranes were blocked with 5% skim milk in a PBS-Tween 0.1%
solution and probed at room temperature for 1h with antibodies
specific to each antigen: phospho-Src (Tyr527; dilution 1:1000),
phospho-Src family (Tyr416; dilution 1:1000) and Src (36D10;
dilution 1:1000) antibody (all from Cell Signaling Technology,
Hertfordshire, UK). An antibody against actin (Abcam, Cambridge,
UK) was used as a loading control. Membranes were subsequently
incubated at room temperature with horseradish peroxidase-
conjugated IgG anti-mouse or anti-rabbit secondary antibodies
for 1h. Supersignal West Femto ECL (Pierce) was used to visualise
protein bands on the membrane.
siRNA treatment
Sub-confluent cell cultures were grown without antibiotics 24h before
transfection in RPMI 1640 medium. A mixture of Lipofectamine 2000
(Invitrogen, Carlsbad, CA, USA) and two different siRNA constructs
(40nM) were incubated in the standard medium with reduced serum
(1%), according to the manufacturer’s instructions. The siRNA
constructs (Stealth) were predesigned and validated (B70% knock-
down) by the manufacturer (Invitrogen). After 24 and 48h, the cells
were harvested and RNA and protein lysates were prepared.
WST-1 assay
Cell proliferation in response to PP1 (10 and 50mM) was measured
by mitochondrial function using the WST-1 proliferation reagent
(Sigma-Aldrich) as described earlier (Narayanan et al, 2005). This
assay measures tetrazolium reductase activity in the mitochondria,
which serves as a measure of cell viability. In short, 96-well plates
were filled with 1250 UM cells per well. At 1 or 3 days (tumour
1–5) and 1 or 6 days (92.1; OCM-1, -3 and -8; Mel-202, -270, -285,
-290, OMM-1, -2.3 and -2.5) after treatment, the WST-1 reagent
was added and absorbance was measured at 450nm on a multiwell
spectrophotometer. The median and standard error of eight wells
were taken at each time and dosage point.
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The cell lines (92.1; OCM-1, -3 and -8; Mel-202, -270, -285, -290,
OMM-1, -2.3 and -2.5) were analysed for Src gene expression.
Primers for Src and the reference gene, b-actin, were developed
with Beacon Designer software (Premier Biosoft, Palo Alto, CA,
USA). Primer sequences for Src: 50-GCTGCGGCTGGAGGTCAA
G-30 (forward) and 50-AGACATCGTGCCAGGCTTCAG-30 (reverse).
Primer sequence for b-actin: 50-CGGGACCTGACTGACTACCTC-30
(forward) and 50-CTCCTTAATGTCACGCACGATTTC-30 (reverse).
The PCR reaction settings were 951C for 5min, then 40 cycles at
961C for 15s and at 601C for 45s. The DNA melting point of the
amplicons was acquired by measuring the fluorescence of SYBR
Green (Bio-Rad, Hercules, CA, USA) during a linear temperature
transition from 70 to 971C at 0.21C each for 10s with accompanying
software (Bio-Rad).
RESULTS
ERK1/2 activation in UM
An antibody array was applied to investigate the MAPK pathway in
10 UM cell lines, in three primary UM and three UM metastasis. We
observed a uniform HSP27 phosphorylation, with the exception of
in three UM cell lines (OCM1, -3, -8). UMs displaying activated
ERK1/2 as well as phosphorylated HSP27 were most common,
whereas signals for phosphorylated ERK1/2 were low in metastasis
tissue (MET1-3) and metastatic UM cell lines (OMM1, OMM2.3 and
OMM2.5) (Figure 1). Remarkably, two of the metastatic cell lines
(OMM2.3, OMM2.5) are derived from the same patient as cell line
Mel270 but contained far less activated ERK1/2.
Differential kinase activity in UM
Reduction of ERK1/2 activation in metastatic cell lines compared
with that in primary UM cell lines provides a model to identify the
underlying mechanism of ERK1/2 activation in the absence of
BRAF and NRAS mutations.
To investigate whether a kinase is differentially activated
between primary UM cell lines and metastatic UM cell lines, we
used peptide-based tyrosine kinase arrays (Lemeer et al, 2007).
The UM cell lines displayed a high kinase activity, whereas the
metastatic UM cell lines displayed a low kinase activity, although
the same amount of lysate was incubated (Figure 2A). After
normalisation, we could analyse the kinase data and identify nine
substrates that were significantly differentially phosphorylated
between primary and metastatic UM cell lines (Figure 2B, Table 1).
Primary UM and metastatic tissue also showed differential
phosphorylation of these nine peptides, although not as clearly
as observed in the cell lines (Figure 2C).
Candidate kinase: Src
We identified nine peptides derived from eight proteins that were
differentially phosphorylated between primary and metastatic cell
line lysates. On the basis of a literature search, we identified
candidate tyrosine kinases for eight out of nine peptides (Table 1)
(Cooper et al, 1983; Thomas and Brugge, 1997; Koike et al, 2003;
Diella et al, 2004). Among the candidates, Src and Src family
members were most prominent. To validate the candidacy of Src,
we performed in vitro inhibition experiments with the Src-kinase-
specific inhibitors PP1 and the PP1 analogue, PP2. We added PP1
and PP2 (10mM) to lysates of primary UM tissue and of a primary
UM cell line and measured the inhibitory effect of these Src
inhibitors using kinase array (Figure 3A). A total of seven out of
nine substrates that identified Src in the first screen displayed a
significantly reduced phosphorylation when PP1 or PP2 were
added to lysates of UM1 and Mel270 (Figure 3A). The PLCG1
peptide and one of the PAX1 (Y31) substrates did not reach
significance but were still phosphorylated at a reduced level after
PP1 and PP2 treatments. The peptide representing FAK1 Y576/
Y577 is a genuine substrate for Src, which was not detected in the
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Figure 1 The MAPK activation in primary UM and UM metastases was studied with a MAPK antibody array. We observed uniform HSP27
phosphorylation in both cell lines and tissue samples, except in OCM1, -3 and -8 (A). Activated ERK1/2 was normalised with HSP27 and shown to be low in
UM metastases (MET1-3), whereas metastatic cell lines just passed the background (OMM1, -2.3, -2.5) (B).
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downregulated by PP1 and PP2 treatments. In the control
experiment, in which we added the inactive analogue of PP1
(PP3) to cell lysates, we did not observe a loss of kinase activity
(not shown).
The kinase activity of metastasis tissue and UM tissue differed
marginally (Figure 2C), and incubation with PP1 (10mM) resulted
in a decimation of kinase activity similar to the inhibition that we
observed in UM tissue (Figure 3B). To validate Src activity, Mel270
was transfected with two siRNA constructs that target Src and
reduced kinase activity (Figure 3B).
Regulation of ERK1/2 and growth
To investigate whether Src contributes to ERK1/2 activation in
Mel270, we analysed the two Src siRNA-transfected cell cultures
with the MAPK antibody array. At 24 and 48h after transfec-
tion with Src siRNA, we observed a reduced ERK1 phosphory-
lation, whereas ERK2 phosphorylation was minimally affected
(Figure 4).
Whether Src inhibition and consequently a lowered ERK
activation in UM cell lines is associated with a reduced growth
was investigated with the WST-1 viability assay (Figure 5). All UM
cell lines showed a PP1-dose and time (1–6 days)-dependent
reduction in cell viability but the magnitude of the response
differed widely. In general, the metastatic UM cell lines were less
affected by PP1. We also determined the growth inhibition rate of
PP1 in cultures of five primary UM cell cultures and observed an
increased sensitivity to PP1 treatment compared with the cell lines.
We had to take samples at day 3 of PP1 treatment because,
thereafter, massive cell death occurred (Figure 5B).
Src protein is reduced in metastasis cell line
Src is regulated by the phosphorylation of tyrosine residues at
position 416 (Y416) and 527 (Y527). The expression of phosphory-
lated Src Y416, which is associated with an active conformation,
was low in the metastatic UM cell lines (Figure 6A). Surprisingly,
the phosphorylation of Y527, which is associated with an inactive
conformation, was also low, and a subsequent analysis indicated
that Src expression is low in metastatic UM cell lines. Therefore, the
difference between kinase activity in metastatic cell lines (OMM1,
OMM2.3 and OMM2.5) and UM cell lines (OCM1, OCM3, OCM8,
Mel202, Mel270, Mel285, Mel290 and 92.1) seems to be the result of
a difference in Src expression.
To investigate the origin of a lowered Src expression, we
performed a gene expression analysis (Figure 6B). Src gene
expression varied widely in the cell lines and in the metastatic cell
lines, but a correlation between protein and gene expression was
not observed in UM cell lines.
A western analysis of Src expression in UM and metastasis
tissue revealed a very high Src expression in only one out of three
primary UM, whereas all three metastasis tissues displayed
medium expression of Src protein (Figure 6C).
DISCUSSION
Constitutive activation of ERK1/2 has often been reported for UM
(Rimoldi et al, 2003; Weber et al, 2003; Zuidervaart et al, 2005).
Using a more quantitative approach, we distinguished a decrease
in active ERK1/2 in metastatic cell lines and in fresh liver
metastasis, suggesting a loss of ERK1/2 activation during UM
progression. The latter is unexpected as ERK1/2 activation is
generally associated with mitogen signalling and is known to
determine malignant potential in vitro. However, in endometrial
and breast cancer, ERK1/2 activation has been associated with a
good prognosis (Milde-Langosch et al, 2005) (Mizumoto et al,
2007). A possible explanation is provided by the observation that
ERK1/2 is involved in oncogene and stress-induced senescence
(Serrano et al, 1997; Stott et al, 1998). This mechanism is thought
to be an important defence for cells that are at risk of neoplastic
transformation and need to be circumvented by tumour cells in
order to proliferate. Loss of activated ERK1/2 may not only relieve
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Figure 2 Tyrosine kinase activity was measured with an array of peptide
substrates. Two representative examples of a UM cell line and a metastatic
cell line (A). Analysis with eBayes identified nine substrates, representing
eight proteins, to be significantly (P¼0.01) differentially phosphorylated
between UM and metastatic cell lines (B). UM (UM1-3) tyrosine kinase
activity is high compared with liver metastasis (MET1-3) (two representa-
tive arrays are shown) (C).
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sthe associated inhibitory mechanisms in a direct manner but may
also require alternative mitogenic signals to take over in UM
metastasis.
Metastatic and UM cell lines provide a unique model to identify
the mechanisms that regulate ERK1/2 activation in UM. Earlier
work already showed that ERK1/2 phosphorylation in UM depends
on the MAPK pathway, although mutations in the usual suspects
(e.g., BRAF and NRAS) are lacking (Calipel et al, 2006). We
investigated the possibility of a tyrosine kinase with differential
activities in UM and UM metastasis to be responsible for ERK1/2
activation, using an array of kinase activity assays. Src was
revealed as a differentially activated tyrosine kinase and this was
supported by incubation with Src-specific kinase inhibitors, PP1
and PP2. Moreover, by treating cell lysates instead of cell cultures,
we minimised the secondary effects of the inhibitors. However,
PP1 and PP2 affect most of the Src family of tyrosine kinases, and
the observed reduction in kinase activity therefore does not
specifically mark Src. Multi-target inhibitors are a problem in
molecular analysis but may be beneficial in clinical application, as,
in CM, a switch from Src to Yes signalling has been reported in
brain metastases (Summy and Gallick, 2003). To specifically
inhibit Src, we targeted the Src gene expression with a siRNA
approach. We detected a reduced kinase activity in Mel270 on
transfection and this was correlated with a reduced ERK1
activation. The ERK2 activation seemed unaffected, which could
be because of the limited efficacy of siRNA treatment, or it could
indicate the activity of another, yet unidentified, kinase. A low Src
protein expression in conjunction with a loss of ERK1/2 activation
in metastatic UM cell lines, however, supports the hypothesis that,
in UM, Src kinase is involved in ERK1/2 activation. Gene
expression analysis revealed no significant differences between
metastatic and UM cell lines, and thereby indicated that post-
transcriptional mechanisms are most likely involved in Src
Table 1 Tyrosine kinase substrates on the kinase array that were differentially phosphorylated between primary UM cell lines and metastatic cell lines
Substrate UniProt ID Position Log fold change Adj. P-value Kinase
CDK2 P24941 T14/Y15 5.3 0.00005 Lyn
FRK P42685 Y387 6.2 0.0002 Unknown
SRC8 Q14247 Y499 4.6 0.006 Src
ENOG P09104 Y43 4.7 0.01 Src
EFS O43281 Y253 3.1 0.01 Src
PLCG1 P19174 Y771 4.2 0.01 Syk, Sky, GFRs
CD79A P11912 Y182/Y188 3.1 0.01 Lyn
PAXI P49023 Y118 4.0 0.02 FAK, Src, Brk
PAXI P49023 Y31 4.3 0.03 FAK, Src, Brk
Tyrosine kinase substrate specificities are included.
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Figure 3 UM1 (06-12) and Mel270 treatment with Src inhibitors (PP1/PP2) identified eight substrates with a significant reduction in phosphorylation (A).
The inhibition of EFS peptide phosphorylation by genetic (Src siRNA) and pharmacological means (PP1) in cell line Mel270, and PP1 treatment of cell lysates
of UM (UM1) and metastasis tissue (MET3) (B).
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Figure 4 ERK1/2 activation in Mel270 24 and 48h after transfection with
Src siRNA. Phosphorylated HSP27 is included as reference signal.
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sdownregulation. Src is both a kinase as well as a client protein for
the chaperone HSP90 that is expressed in UM (Missotten et al,
2003). Whether HSP90 is reduced in metastases and whether
treatment with HSP90 inhibitors depends on Src signalling is part
of future investigation (Babchia et al, 2008; Faingold et al, 2008).
The inhibition of Src kinase activity resulted in a strong growth
reduction in all UM cultures, whereas in UM cell lines, the
response varied more widely. The genetic background of the cell
lines might play a role in the observed variation. However, all UM
cell lines displayed Src kinase activity and PP1 sensitivity,
irrespective of c-kit upregulation (Mel270) or the BRAF V600E
(OCM1) and GNAQ Q209L (Mel202) mutation status (Lefevre et al,
2004; Van Raamsdonk et al, 2008). Tissue of UM and UM liver
metastasis displayed more or less comparable Src levels. The
incubation of lysates with Src inhibitors resulted in a comparable
reduction of kinase activity in UM and metastasis tissue. The
possibility that there exist Src negative clones in liver metastasis
can, however, not be ruled out on the basis of these data. Clinical
trials targeting Src kinase activity in UM should therefore
anticipate this potential risk.
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sIn conclusion, we have identified a differential ERK1/2
activation in UM and metastatic UM cell lines. Using tyrosine
kinase activity profiling, we identified Src as a determinant of
ERK1/2 activation and showed that Src expression and kinase
activity, together with ERK1/2 activation, are reduced in UM
metastases cell lines.
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